Researchers in a 2026 guideline review provide evidence-based recommendations from ESHRE on ovarian stimulation for IVF/ICSI, covering protocols, medications, monitoring, and safety.
Poor ovarian response
Researchers in a 2026 randomized trial found that ~9 weeks of transdermal testosterone before IVF didn’t improve pregnancy rates or egg numbers in women with diminished ovarian reserve.
Researchers in a 2026 meta-analysis combined 15 randomized trials in women with POR or DOR and found that while some forms of acupuncture were linked to slightly more eggs retrieved, they didn’t improve pregnancy rates.
A 2026 study found that a microfluidic device called FIND-Chip can recover additional eggs from follicular fluid that may have been missed by manual searching after an egg retrieval, with one live birth reported.
A 2025 meta-analysis combined the results of 22 studies and found no clear improvement in live birth rates from hormonal add-on for poor ovarian response, though growth hormone and testosterone ranked as the most promising options, and growth hormone increased the number of eggs retrieved.
A large 2025 study charts how AMH levels decline with age in over 22,000 women, revealing when diminished ovarian reserve (DOR) becomes more common, regardless of infertility status.
A new study found that selecting FSH type based on a woman’s FSH receptor (FSHR) genotype may improve IVF pregnancy and live birth rates, particularly when using rFSH for NN genotypes and uFSH for NS or SS genotypes.
A 2025 study compared cumulative live birth rates for patients transferring up to 15 untested embryos. Besides the CLBR based on single blastocyst transfers and age, they found differences based on ovarian response and blastocyst formation rates. They also suggested a new way to define recurrent implantation failure.
A 2024 meta-analysis combined the results of 12 studies comparing different IVF trigger shots, including hCG, GnRH agonist, and dual and double triggers. Triggers showed variable outcomes, highlighting the need for a personalized medicine approach.
A 2024 meta-analysis combined the results of 38 studies investigating treatments for diminished ovarian reserve patients. DHEA, testosterone, high-dose gonadotropins and delayed start protocols all improved the number of eggs retrieved.
Researchers in a 2024 study performed an RCT and found that intraovarian PRP resulted in an increased number of eggs retrieved in patients with poor ovarian response, although these eggs weren’t more likely to become blastocysts or be euploid after PGT-A and resulted in fewer pregnancies.
